BCMA-specific iPSC-derived CTL

BCMA-specific iPSC-derived CTL is an experimental, research-stage adoptive cell therapy designed for the treatment of multiple myeloma. The therapy involves the epigenetic reprogramming of exhausted BCMA (B-cell maturation antigen)-specific CD8+ T cells into induced pluripotent stem cells (iPSCs) using defined transcription factors (OCT3/4, SOX2, KLF4, and c-MYC). These iPSCs are subsequently re-differentiated into rejuvenated, antigen-specific cytotoxic T lymphocytes (CTLs). This approach aims to overcome the limitations of T-cell exhaustion and senescence typically observed in conventional adoptive T-cell therapies. The resulting CTLs exhibit early lineage memory features, lack significant immune checkpoint expression, and demonstrate high anti-tumor activity against BCMA-expressing multiple myeloma cells. Research on this asset has been primarily conducted by academic institutions including the Dana-Farber Cancer Institute and the Laboratory of Regenerative Immunotherapy at Kyoto University.

Other names

BCMA-specific iPSC-derived CD8+ T cellsBCMA-specific iPSC-derived cytotoxic T lymphocytesBCMA-specific CD8+ cytotoxic T lymphocytes using induced pluripotent stem cell technology